Health news reports on HCA Healthcare's profit forecast amidst insurance uncertainty, Centene's focus on profitability, and adjustments to the Tour de France due to a cattle disease. Sarepta's gene therapy faces EU scrutiny,

Health insurers are navigating rising costs and regulatory challenges, with Centene (CNC) slashing its forecast amid ACA uncertainties. Arthur Wong, S&P Global Ratings healthcare managing director, and Adriel Bettelheim,

It’s pretty shocking just how poorly the health insurance names are trading. Centene–a major Obamacare and Medicaid insurer–is down 57% this month. Its stock price after earnings this morning hit 2014 levels.

Tesla, UnitedHealth Group, Berkshire Hathaway, Centene, Elevance Health, T-Mobile US, and Wells Fargo & Company are the seven Insurance stocks to watch today, according to MarketBeat's stock screener tool.

Health coverage company Centene (NYSE:CNC) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 22.4% year on year to $48.74 billion. Its non-GAAP loss of $0.16 per share was significantly below analysts’ consensus estimates.

The managed-care specialist's troubles began in April when its quarterly results were overshadowed by membership declines in Medicaid and Medicare. Centene in July then withdrew its financial guidance for 2025 after warning that its earnings would fall well short of expectations.